1 week Ago By Defense World Staff
Bank of Montreal Can grew its stake in Geron Co. ( NASDAQ:GERN – Free Report ) by 38.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 33,147 shares of the biopharmaceutical company’s stock after buying an additional 9,277 shares during the period. Bank of Montreal Can’s holdings in Geron were worth $117,000 at the end of the most recent reporting period. A number of other institutional investors have also recently made changes to their positions in the stock.
Segall Bryant & Hamill LLC increased its stake in Geron by 82.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 7,446,275 shares of the biopharmaceutical company’s stock valued at $26,360,000 after acquiring an additional 3,369,196 shares during the last quarter.
Vanguard Group Inc. increased its position in shares of Geron by 3.4% during the 4th quarter.
Vanguard Group Inc. now owns 33,538,822 shares of the biopharmaceutical company’s stock valued at $118,727,000 after purchasing an additional 1,088,912 shares during the last quarter. World Investment Advisors LLC raised its holdings in shares of Geron by 10,151.
4% during the 3rd quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company’s stock valued at $4,674,000 after buying an additional 1,019,510 shares in the last quarter. Exome Asset Management LLC bought a new stake in Geron in the 3rd quarter worth approximately $4,109,000.
Finally, Wellington Management Group LLP boosted its stake in Geron by 6.7% in the fourth quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company’s stock worth $47,826,000 after buying an additional 847,710 shares in the last quarter.
Institutional investors own 73.71% of the company’s stock. Wall Street Analysts Forecast Growth GERN has been the subject of a number of research reports.
Barclays reaffirmed an “overweight” rating and issued a $4.00 price objective (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th.
Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. Stifel Nicolaus lowered their target price on Geron from $8.
00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. B.
Riley lowered Geron from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $3.50 to $2.00 in a research report on Thursday, February 27th.
Finally, HC Wainwright reiterated a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Geron presently has an average rating of “Moderate Buy” and a consensus target price of $5.
75. Geron Stock Performance NASDAQ:GERN opened at $1.42 on Friday.
The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.
04. The firm’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $2.
92. The stock has a market cap of $904.42 million, a P/E ratio of -4.
44 and a beta of 0.66. Geron Co.
has a twelve month low of $1.17 and a twelve month high of $5.34.
Geron ( NASDAQ:GERN – Get Free Report ) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.
04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.
53%. The company had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.
29 million. As a group, research analysts predict that Geron Co. will post -0.
25 EPS for the current year. Geron Company Profile ( Free Report ) Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Read More Five stocks we like better than Geron 3 Grocery Stocks That Are Proving They Are Still Essential Markets Think Robinhood Earnings Could Send the Stock Up Stock Average Calculator Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? How to Invest in Insurance Companies: A Guide AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. ( NASDAQ:GERN – Free Report ).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter ..
